Works about RIVAROXABAN

Results: 1544
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13

    Assessment of trough rivaroxaban concentrations on markers of coagulation activation in nonvalvular atrial fibrillation population.

    Published in:
    Heart & Vessels, 2017, v. 32, n. 5, p. 609, doi. 10.1007/s00380-016-0912-0
    By:
    • Kitagawa, Fumihiko;
    • Ishii, Junnichi;
    • Hiramitsu, Shinya;
    • Takahashi, Hiroshi;
    • Okuyama, Ryuunosuke;
    • Kawai, Hideki;
    • Muramatsu, Takashi;
    • Harada, Masahide;
    • Motoyama, Sadako;
    • Naruse, Hiroyuki;
    • Matsui, Shigeru;
    • Sarai, Masayoshi;
    • Hayashi, Mutsuharu;
    • Watanabe, Eiichi;
    • Izawa, Hideo;
    • Ozaki, Yukio
    Publication type:
    Article
    14
    15
    16
    17
    18
    19
    20
    21
    22

    AN OVERVIEW OF THE PHARMACEUTICAL PROFILE OF RIVAROXABAN.

    Published in:
    Farmacia, 2025, v. 73, n. 1, p. 1, doi. 10.31925/farmacia.2025.1.1
    By:
    • SOLOMON, CRISTINA;
    • NIȚĂ, DENISA TEODORA;
    • OZON, EMMA ADRIANA;
    • FIȚA, ANCUȚA CĂTĂLINA;
    • VIZITEU, HORAȚIU MARIUS;
    • MUSUC, ADINA MAGDALENA;
    • SÂRBU, IULIAN;
    • MITU, MIRELA ADRIANA
    Publication type:
    Article
    23
    24
    25
    26
    27

    Quality of life with rivaroxaban in patients with non-valvular atrial fibrilation by therapeutic compliance.

    Published in:
    2017
    By:
    • Márquez-Contreras, Emilio;
    • Martell-Claros, Nieves;
    • Gil-Guillén, Vicente;
    • Figuera-Von Wichmann, Mariano;
    • Sánchez-López, Eugenio;
    • Gil-Gil, Ines;
    • Márquez-Rivero, Sara;
    • Márquez-Contreras, Emilio;
    • Gil-Guillén, Vicente;
    • De la Figuera-Von Wichmann, Mariano;
    • Sánchez-López, Eugenio;
    • Márquez-Rivero, Sara;
    • Working Group on Compliance and Inertia. Spanish Society of Hypertension
    Publication type:
    journal article
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38

    Prophylactic rivaroxaban in the early post-discharge period reduces the rates of hospitalization for atrial fibrillation and incidence of sudden cardiac death during long-term follow-up in hospitalized COVID-19 survivors.

    Published in:
    Frontiers in Pharmacology, 2023, p. 1, doi. 10.3389/fphar.2023.1093396
    By:
    • Fiedler, Lukas;
    • Motloch, Lukas J.;
    • Dieplinger, Anna-Maria;
    • Jirak, Peter;
    • Davtyan, Paruir;
    • Gareeva, Diana;
    • Badykova, Elena;
    • Badykov, Marat;
    • Lakman, Irina;
    • Agapitov, Aleksandr;
    • Sadikova, Liana;
    • Pavlov, Valentin;
    • Föttinger, Fabian;
    • Mirna, Moritz;
    • Kopp, Kristen;
    • Hoppe, Uta C.;
    • Pistulli, Rudin;
    • Benzhi Cai;
    • Baofeng Yang;
    • Zagidullin, Naufal
    Publication type:
    Article
    39
    40
    41
    42
    43

    Clinical profile and outcomes in very elderly patients with atrial fibrillation anticoagulated with rivaroxaban: data from the EMIR study.

    Published in:
    Journal of Geriatric Cardiology, 2024, v. 21, n. 7, p. 723, doi. 10.26599/1671-5411.2024.07.003
    By:
    • Marín, Francisco;
    • Sánchez, Manuel Anguita;
    • Lekuona, Iñaki;
    • Fernández, Marcelo Sanmartín;
    • Barrios, Vivencio;
    • Muñoz, Carlos Perez;
    • Cosín-Sales, Juan;
    • Pérez Cabeza, Alejandro I.;
    • Schilling, Vanesa Roldán;
    • Priu, Carles Rafols;
    • Orenes-Piñero, Esteban;
    • Esteve-Pastor, María Asunción
    Publication type:
    Article
    44
    45
    46
    47
    48
    49
    50